Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01213251 · ClinicalTrials.gov registry record · Phase 2
Post-Myocardial Infarction Remodeling Prevention Therapy
A Phase 2 study, sponsored by Medtronic Cardiac Rhythm and Heart Failure.
- Completed
- Registry status
- Phase 2
- Development phase
- 129
- Enrollment target
NCT01213251 is a Phase 2 study that has completed, run by Medtronic Cardiac Rhythm and Heart Failure. The registered enrollment target is 129 participants.
The verdict
NCT01213251, a Phase 2 study, has completed, sponsored by Medtronic Cardiac Rhythm and Heart Failure.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 129 participants
- Enrollment target
Study Summary
The purpose of this study is to demonstrate the feasibility of pacing as a therapy to prevent adverse remodeling of the myocardium following an acute myocardial infarction (MI) in patients at highest risk for adverse myocardial remodeling.
Interventions
- DEVICE Single Site Pacing
- DEVICE Dual Site Pacing
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 129 participants |
| Start Date | 2010-12 |
| Est. Completion | 2016-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01213251
The ClinicalTrials.gov registry entry for NCT01213251 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 129 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medtronic Cardiac Rhythm and Heart Failure, which has 115 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Single Site Pacing is the first listed.
NCT01213251 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01213251 about?
NCT01213251 is a clinical study titled "Post-Myocardial Infarction Remodeling Prevention Therapy". The purpose of this study is to demonstrate the feasibility of pacing as a therapy to prevent adverse remodeling of the myocardium following an acute myocardial infarction (MI) in patients at highest risk for adverse myocardial remodeling.
What is the current status of trial NCT01213251?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 129 participants. The study started on 2010-12. Estimated completion is 2016-04.
What interventions are being tested in trial NCT01213251?
The interventions under investigation include: Single Site Pacing (DEVICE), Dual Site Pacing (DEVICE).
Who is sponsoring clinical trial NCT01213251?
This trial is sponsored by Medtronic Cardiac Rhythm and Heart Failure, which has 115 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.